Development and Validation of a Simple and Robust Bioanalytical Method to the Quantification of Tafamidis in Human Plasma using LC-MS/MS

ABSTRACT

Objectives: Amyloid diseases are a rare class of disorders that have gained significant attention for therapeutic advancements. Among the key proteins implicated, transthyretin plays a central role in the progression and clinical symptoms of these diseases. Tafamidis, an approved therapeutic agent, has demonstrated considerable efficacy in mitigating symptoms associated with transthyretin-related amyloid conditions. Despite its clinical significance, robust bioanalytical methodologies for the accurate quantification of Tafamidis in biological matrices remain limited. Materials and Methods: This study focuses on the development and validation of a precise bioanalytical method to quantify Tafamidis in human plasma using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). The method was calibrated over a range of 5-4000 ng/mL, with chromatographic separation performed using an isocratic mobile phase on a Gemini NX C18 column. Mass transitions were optimized at 307.400 → 262.400 for Tafamidis and 313.900 → 270.000 for Tafamidis-13C6. A liquid-liquid extraction approach ensured efficient recovery of Tafamidis from plasma. Results and Discussion: Validated per USFDA regulatory guidelines, the method demonstrated excellent precision, accuracy, and stability, with correlation coefficients exceeding 0.99 and recovery rates reaching 70%. Stability was confirmed for up to 10 days in matrix and aqueous samples. Conclusion: This robust, validated method offers high reliability and suitability for analytical applications and quantitative clinical investigations involving Tafamidis.

KEYWORDS

• Amyloid Diseases
• Transthyretin
• Protein
• Method development
• Method validation

Showing references and in-text citations exactly as published.

• DOI10.5530/ijper.20262396Copy

RELATED ARTICLES

Matched on section and article type within this issue of IJPER.

• Article · VOLUME 60, ISSUE 4SFormulation and Evaluation of Liquisolid Tablet with Enhanced Dissolution of Ivacaftor by Using Box-Behnken DesignManisha Dnyanoba Chate, Swaroop Rameshwarji Lahoti · pp. s1405–s1415Original ArticleSame type: Article
• Article · VOLUME 60, ISSUE 4SDevelopment and Evaluation of Polymer-conjugated Solid Fast Dissolving Tablets of Ambroxol HydrochlorideVidhan Chand Bala, Mukesh Kumar Singh, Amit Kumar, Arvind Kumar Patel, Sunil Kumar Tiwari, Asheesh Kumar Gupta, Sushil Kumar · pp. s1416–s1429Original ArticleSame type: Article
• Article · VOLUME 60, ISSUE 4SQuality by Design Development of a Thermosensitive in situ Gel for Enhanced Ocular Delivery of CarvedilolAnurag Rajendra Panade, Sandip Akaram Bandgar, Riya Raghunath Patil, Indrayani Sandip Bandgar · pp. s1430–s1444Original ArticleSame type: Article
• Article · VOLUME 60, ISSUE 4SNovel Application of Mixed Solvency Concept for the Development of Topical Emulgel Formulations of Poorly Water-Soluble Drug, Piroxicam, and their EvaluationsJitendra Singh, Prateek Sahu, Sharad Prakash Pandey, Rajesh Kumar Maheshwari · pp. s1445–s1460Original ArticleSame type: Article